Sai Life Sciences IPO is a book-built issue with a total size of ₹3,042.62 crore. The offering comprises a fresh issue of 1.73 crore equity shares, aggregating to ₹950 crore, and an offer for sale of 3.81 crore shares, totaling ₹2,092.62 crore.
The subscription window for Sai Life Sciences IPO opens on December 11, 2024, and closes on December 13, 2024. The allotment is expected to be finalized on Monday, December 16, 2024, with the shares scheduled to list on the BSE and NSE on Wednesday, December 18, 2024.
Sai Life Sciences operates in the pharmaceutical sector, specifically focusing on contract research, development, and manufacturing services (CRDMO). They provide end-to-end services for small-molecule new chemical entities (NCEs) and collaborate with leading pharmaceutical and biotechnology companies.
The IPO price band is set between ₹522 and ₹549 per share. Retail investors are required to apply for a minimum lot size of 27 shares, requiring an investment of ₹14,823 at the upper price limit. Small Non-Institutional Investors (sNII) must apply for a minimum of 14 lots, or 378 shares, amounting to ₹207,522. Big Non-Institutional Investors (bNII) must apply for 68 lots, or 1,836 shares, translating to ₹1,007,964.
Kotak Mahindra Capital Company Limited, Jefferies India Private Limited, Morgan Stanley India Company Pvt Ltd, and IIFL Securities Ltd are the book-running lead managers for this IPO, with Kfin Technologies Limited acting as the registrar.
Sai Life Sciences IPO Details:
| Company Name | Sai Life Sciences Limited |
| Sector | Contract Research, Development and Manufacturing |
| IPO Type | Mainboard |
| IPO Open date | 11th Dec 2024 |
| IPO Close date | 13th Dec 2024 |
| OFS | |
| Listing Exchanges | NSE, BSE |
| Share Holding Pre-issue | |
| DRHP Draft Prospectus | Click to check |
| RHP Draft Prospects | Click to check |
Sai Life Sciences IPO Lot Size:
| Application | Lot Size | Shares | Amount |
| Retail (Min) | 1 | 27 | 14,823 |
| sHNI (Min) | 14 | 378 | 2,07,522 |
| bHNI (Min) | 68 | 1836 | 10,07,964 |
Sai Life Sciences IPO Timeline:
| IPO Open Date | 11th Dec 2024 |
| IPO Close Date | 13th Dec 2024 |
| Basis of Allotment | 16th Dec 2024 |
| Refund Initiation Date | 17th Dec 2024 |
| Shares Credit to Demat | 17th Dec 2024 |
| Listing Date | 18th Dec 2024 |
Things to Consider before applying for an IPO
Financial Performance: Review Sai Life Sciences’ Financials to understand its revenue, profitability, and growth prospects.
Industry Outlook: Consider the overall health of India’s Contract Research, Development and Manufacturing Industry.
Valuation: Compare the price band to similar companies in the industry to see if the IPO is priced fairly.
Management Team: Research the experience and capabilities of the management team.
Our Verdict
This IPO offers a good opportunity to invest in Sai Life Sciences and be a part of its growth.
FAQ
What is Grey Market Premium (GMP)?
The Grey Market Premium (GMP) represents the price at which an Initial Public Offering (IPO) is traded in the unregulated grey market before its official listing. It serves as an indicator of how the IPO might perform on the listing day. Seeing the latest GMP, investors can estimate the listing performance of the IPO.
